LivaNova
(Nasdaq: LIVN)
today announced it appointed Ahmet Tezel as chief innovation officer, effective May 13, 2024.
Tezel will take on the newly created chief innovation officer position to establish an integrated innovation function at the company and accelerate the development of new technologies.
“I am very pleased to welcome Ahmet to the LivaNova team. At LivaNova, our commitment to pioneering innovation remains unwavering, and Ahmet’s arrival marks a significant step in advancing this vision. With a remarkable track record, Ahmet has led teams that have developed market-leading technologies across diverse medical domains, from bariatric surgery to surgical ophthalmology. As Chief Innovation Officer, Ahmet will advance LivaNova’s ability to create novel solutions and elevate the quality of care in neurological and cardiac health for patients around the world,” CEO Vladimir Makatsaria said in a news release.
With over 20 years of R&D experience, Tezel joins London-based LivaNova after leading the global R&D and innovation teams at Johnson & Johnson MedTech. He has also held executive R&D roles at several healthcare companies, including Ethicon, Alcon and Allergan, developing Class III implantable and complex capital equipment.
“I look forward to this new chapter at LivaNova, working with the team to harness their motivations and talents to drive innovative product development that creates long-term value for the Company and aligns with its mission,” said Tezel. “I am honored to join a company that has a profound impact on patients.”